Clinical Response and Tolerability of Selinexor in Acute Myeloid Leukemia and Other Hematologic Malignancies - a Systematic Review

Conclusion:Selinexor based combination regimens have shown better clinical response against AML as compared to monotherapy. The efficacy results in multiple myeloma and other hematological malignancies are also encouraging. The adverse events like cytopenias were common as in other chemotherapy regimens.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Tariq, M. J., Yasir, M., Khalid, A., Amin, S. N., Samuel, S., Khalil, M. J., Aslam, S., Ahmad, M. Q., Fraz, M. A., Usman, M., Ijaz, A., Farooqui, A. A., Durer, S., Durer, C., Anwer, F. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation Source Type: research